CT-2103: A novel macromolecular taxane with potential advantages compared with conventional taxanes

Clinical Lung Cancer

Volumn 6, Issue SUPPL. 2, 2004, Pages

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Apoptosis; Macromolecular drug conjugate; Mitotic arrest; Neuropathy; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; GLYCOPROTEIN P; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM; POLYMER; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; NEUTROPENIA; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; VOMITING;

EID: 12744269417     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.s.020     Document Type: Article

References (23)

1. Gridelli C. Chemotherapy of advanced non small cell lung cancer in the elderly: an update. Crit Rev Oncol Hematol 2000; 35:219-225.
2. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 2002; 20:23S-33S.
3. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5 (suppl 6):S3-S6.
4. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glucamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003; 519:81-99.
5. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2:347-360.
6. Gelderblom H, Verweij J, Nooter K, et al. the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
7. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-1268.
8. Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003; 42:1089-1105.
9. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46:6387-6392.
10. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2:347-360.
11. Luzio JP, Poupon V, Lindsay MR, et al. Membrane dynamics and the biogenesis of lysosomes. Mol Membr Biol 2003; 20:141-154.
12. Avendano C, Menendez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002; 9:159-193.
13. Chico JF, Liang JA, Hsu WH, et al. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003; 181:267-273.
14. Hsia TC, Lin CC, Wang JJ, et al. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002; 180:173-179.
15. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992; 17:18-21.
16. Bernareggi A, Oldham F, Barone C. Xyotax™ (paclitaxel poliglumex; CT-2103). Pharmacokinetic evidence for an enhanced permeability and retention effect. Ann Oncol 2004; 15(suppl 3): iii103 (Abstract #385).
17. Bodkin D, Neubauer M, Bolton MG. Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small cell lung cancer who are > 69 years of age or who have performance status (PS) = 2. Eur J Cancer 2003; 1 (suppl):S242 (Abstract #806).
18. Lilenbaum R, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21: 1a (Abstract #2).
19. Nemunaitis J. Phase 1 study of Xyotax (CT-2103) and carboplatin in patients with solid tumors. Eur J Cancer 2003; 1(suppl):S171 (Abstract #566).
20. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
21. Sabbatini P, Aghajanian C, Dizon D, et al. CT-2103 (XYOTAX) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: results of a phase II study. J Clin Oncol 2004; 22:4523-4531.
22. Langer CJ. Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax). Oncologist 2004; 9:398-405.
23. Skubitz K, Kudelka A, Bolton MG. Phase 1 study of CT-2103/cisplatin in solid tumors. Eur J Cancer 2003; 1(suppl :S168 (Abstract #554).